NCT06251492

Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)：a Prospective, Single-arm, Phase II Clinical Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the efficacy of 2 cycles of combinatory adebrelimab and stereotactic radiotherapy, followed by monotherapy adebrelimab in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.

Conditions

• Prostate Cancer Metastatic
• Castration-resistant Prostate Cancer

Interventions

Type	Name	Description
RADIATION	Stereotactic body radiotherapy	8 Gray x 3 for 2 cycles
DRUG	Adebrelimab	Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression

Timeline

• Start date: 2024-01-30
• Primary completion: 2025-07-30
• Completion: 2025-12-30
• First posted: 2024-02-09
• Last updated: 2024-02-20

Locations

3 sites across 1 country: China